These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8519672)

  • 41. Pretreatment natural killer antigen density correlates to clinical response in tumor patients receiving long-term subcutaneous recombinant interleukin-2 and recombinant interferon-alpha.
    Duensing S; Hadam M; Körfer A; Schomburg A; Menzel T; Grosse J; Kirchner H; Poliwoda H; Atzpodien J
    Mol Biother; 1992 Dec; 4(4):170-3. PubMed ID: 1282326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study.
    Elias L; Lew D; Figlin RA; Flanigan RC; Thompson ME; Triozzi PL; Belt RJ; Wood DP; Rivkin SE; David E
    Cancer; 2000 Aug; 89(3):597-603. PubMed ID: 10931459
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer.
    Négrier S; Caty A; Lesimple T; Douillard JY; Escudier B; Rossi JF; Viens P; Gomez F
    J Clin Oncol; 2000 Dec; 18(24):4009-15. PubMed ID: 11118461
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
    Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
    J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta].
    Schenck M; Börgermann C; Jäger T; vom Dorp F; Sperling H; Rübben H; Lümmen G
    Urologe A; 2007 May; 46(5):528-34. PubMed ID: 17356836
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer.
    Pavone L; Andrulli S; Santi R; Majori M; Buzio C
    Cancer Immunol Immunother; 2001 Apr; 50(2):82-6. PubMed ID: 11401029
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha.
    Jacobs EL; Clare-Salzler MJ; Chopra IJ; Figlin RA
    J Immunother (1991); 1991 Dec; 10(6):448-55. PubMed ID: 1768679
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
    Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
    J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
    Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-alpha.
    Atzpodien J; Körfer A; Palmer PA; Franks CR; Poliwoda H; Kirchner H
    Ann Oncol; 1990 Sep; 1(5):377-8. PubMed ID: 2261378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sequential interleukin-2 and alpha interferon for renal cell carcinoma and melanoma.
    Thomas H; Barton C; Saini A; Dalgleish A; Waxman J
    Eur J Cancer; 1992; 28A(6-7):1047-9. PubMed ID: 1627371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma].
    Fujinami K; Ikeda I; Miura T; Kondo I
    Gan To Kagaku Ryoho; 1996 Oct; 23(12):1689-91. PubMed ID: 8886046
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A combination of vinblastine and doxorubicin with interferon alpha.
    Jekunen A; Pyrhönen S
    Am J Clin Oncol; 1996 Aug; 19(4):384-5. PubMed ID: 8677910
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
    Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
    Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma: efficacy of low doses.
    Cetto GL; Franceschi T; Turrina G; Chiarion-Sileni V; Capelli MC; Bellini A; Paccagnella A; Bassetto MA; Molino AM; de Sandre G
    Semin Surg Oncol; 1988; 4(3):184-90. PubMed ID: 3055162
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
    Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
    J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
    Ravaud A; Négrier S; Cany L; Merrouche Y; Le Guillou M; Blay JY; Clavel M; Gaston R; Oskam R; Philip T
    Br J Cancer; 1994 Jun; 69(6):1111-4. PubMed ID: 8198979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study.
    Bergmann L; Weidmann E; Mitrou PS; Runne U; Keilholz U; Bartsch HH; Franks CR
    Onkologie; 1990 Apr; 13(2):137-40. PubMed ID: 2197585
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
    Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
    Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.